Skip to main
AUTL
AUTL logo

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics demonstrates a promising financial outlook supported by its clinical-stage pipeline, particularly with the positive safety and efficacy data for Aucazyl, which shows potential to outperform competitors in the CAR-T space. The company is also positioned to achieve significant gross margins of 60-70% due to improvements in manufacturing processes and increased utilization. Furthermore, the anticipated long-term benefits of its therapies, as indicated by decreased exhaustion markers and the positive feedback from regulatory bodies, bolster the potential for sustained success in its cancer treatment strategies.

Bears say

Autolus Therapeutics's sales are anticipated to remain flat in Q3 2025 due to alterations in CMS reimbursement policies, casting uncertainty on future revenue growth. The company's production capacity of CAR-T therapeutics is projected to fall short of initial forecasts, which may hinder its ability to meet market demand. Additionally, the presence of significant adverse events associated with its therapies, such as cytokine release syndrome and neurotoxicity, raises concerns about their broader application and acceptance in the market.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.